Clinical Trials

182 enrolled

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07354984 2026-01-21

PIONEER-HN

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

10 enrolled

Pathologic Complete Response, Head and Neck Neoplasms

NCT06509009 2025-09-19

Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

30 enrolled

Nasopharyngeal Carcinoma

NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

208 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT06912711 2025-05-21

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

70 enrolled

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT04223024 2025-03-05

Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma

246 enrolled

Nasopharyngeal Carcinoma

NCT03025958 2024-05-06

Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

30 enrolled

Nasopharyngeal Carcinoma

NCT06259721 2024-03-07

Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

22 enrolled

Nasopharyngeal Carcinoma

NCT03708822 2024-01-18

Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

48 enrolled

Nasopharyngeal Carcinoma

NCT00702481 2023-02-28

Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer

32 enrolled

Head and Neck Neoplasms

NCT04508816 2022-04-04

Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

45 enrolled

Nasopharyngeal Carcinoma

NCT04367909 2021-11-08

A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma

68 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05024019 2021-08-27

Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery

95 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04882462 2021-05-12

Carpp-1

100 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03915132 2021-01-29

Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma

47 enrolled

Nasopharyngeal Carcinoma

NCT03557112 2018-11-02

By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC

180 enrolled

Nasopharyngeal Carcinoma

NCT03666221 2018-09-11

Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

67 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT01616849 2015-09-22

Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma

39 enrolled

Nasopharyngeal Carcinoma

NCT01425736 2014-06-03

Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma

91 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT01516996 2012-03-20

Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer

80 enrolled

Hypopharyngeal Neoplasms, Oropharyngeal Neoplasms

NCT00910117 2012-02-20

Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

40 enrolled